The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
about
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot studyEffect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trialEfficacy of pain education in cancer patients: a meta-analysis of randomized controlled trials.Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).Patients´ experiences of pain following day surgery - at 48 hours, seven days and three months.Preliminary development and validation of a new end-of-life patient-reported outcome measure assessing the ability of patients to finalise their affairs at the end of life.Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?Biomarker development in the context of urologic cancersNovel Noxipoint Therapy versus Conventional Physical Therapy for Chronic Neck and Shoulder Pain: Multicentre Randomised Controlled Trials.Mindful Yoga for women with metastatic breast cancer: design of a randomized controlled trialCharacterizing pain and associated coping strategies in methadone and buprenorphine-maintained patientsImpact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes.Statistical aspect of translational and correlative studies in clinical trials.Effects of Dexamethasone and Placebo on Symptom Clusters in Advanced Cancer Patients: A Preliminary Report.Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.A comparison of straight- and curved-path walking tests among mobility-limited older adults.IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studiesPatient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.Validation and clinical utility of prostate cancer biomarkers.Measuring pain in patients undergoing hemodialysis: a review of pain assessment tools.Psychometric validation of the Brief Pain Inventory-Short Form in patients with systemic lupus erythematosus in the United States.Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.Cognitive Testing of an Electronic Version of the Faces Pain Scale-Revised with Pediatric and Adolescent Sickle Cell Patients.Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain.A multicenter, prospective trial to assess the safety and performance of the spinal modulation dorsal root ganglion neurostimulator system in the treatment of chronic pain.Dysmenorrhea, the menstrual cycle, and sleep.Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.Pain in castration-resistant prostate cancer with bone metastases: a qualitative study.Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain.Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.Assuring the patient centeredness of patient-reported outcomes: content validity in medical product development and comparative effectiveness research.Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.Acupuncture for treatment of uncontrolled pain in cancer patients: a pragmatic pilot study.A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) studyCo-occurrence of posttraumatic stress symptoms, pain, and disability 12 months after traumatic injury.Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment.Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials.Prospective Audit of a Pathway for In-Patient Pain Management of Chronic Abdominal Pain: A Novel and Cost-Effective Strategy.
P2860
Q33684190-A1BD41FA-1AB2-4177-8B8A-F4F122570797Q33796889-F0C13DD7-680C-4E97-8EA6-B948E3D7E7ABQ34336573-3BCFEA07-97B6-430C-BA8C-3C0F91F85827Q34594636-4CD15AEB-6C45-4AA5-8910-FBD08F34EB39Q34709065-412A369E-EC1A-436B-8C7F-1E72DD81EC4EQ35107722-11037112-D27B-47CE-9F61-8EF07DD0EFE8Q35148891-71F17868-4DF8-40F5-9FF0-E0442B6E6390Q35857652-44F34C2C-EA22-409B-BE93-064AA6A51110Q35906352-2643C246-42D3-4885-AEEF-BA84AC85EC76Q36265910-7845E0A2-1666-4457-99E5-111AC281482FQ36306650-044863BF-23FA-424C-A792-DB62F47A336DQ36328256-0FD4DDE9-CE72-44EC-BA03-C2D7ED95934FQ36497041-2A3CB8A2-FA27-4DB6-A6D5-53EA9725495DQ36658054-2713BF23-0639-4F15-BC8E-51FC4EBDC2F0Q36673441-A9E51093-7DBE-4ED3-91B1-D28D162C33A5Q37230455-1344BED5-9728-41ED-9F90-BDF6034CD4CAQ37270870-C8E33716-3243-497A-BC86-59D04B4F5B2CQ37291510-F6D0BE2E-9A31-494A-82A3-01B2F5F0EFEBQ37536304-1C936DBE-C60F-4676-9056-12A889375BEBQ38086420-F5E785B4-119F-4FBF-9DBB-CF559FB3CC88Q38411165-642F1594-5A6F-40A9-86B1-558AD0A2D1F6Q38514172-153D9160-ADEB-4640-A8E9-278C2E029093Q38603148-EA185D7B-0831-4117-BC63-1CA56FF74536Q38793068-C003865C-4D6B-4C52-9521-F8A30B56147BQ38868066-52815E52-5851-486B-B006-1729F5B5EB6FQ39202228-870C8365-6C01-442F-B81C-B726A9D97405Q39227529-8F672051-1B67-42FF-9C08-2D6260EC02EDQ39253235-E9E07782-E653-4548-AD5C-3E23578A22A2Q39289330-7870D0DC-A801-4D7C-BB2D-288D7F5ECCC9Q39322019-133C0018-A329-4C27-8B41-653E8A3962E1Q39368345-6E6A7547-5FD1-44E1-93E9-67530F95CF8AQ41530676-FA51F08A-6FC3-4F65-8580-77F5D5F23A4DQ43135988-CBDA54D7-F83B-4CF4-93C7-25E58D5605A3Q44850061-BEF9E8B0-89A2-4995-A02E-95A1D170CAEDQ46300114-6EAAA966-5F8E-4AB5-B167-703F7F4CFDD0Q47125009-700C1089-0AF4-4B77-9691-2C33A5706488Q47638936-46C92B37-E0F8-4F83-820E-CA8245CB0A7FQ47872020-600B4278-AE56-48B9-A43C-E04F607FDD8AQ48260186-311C7BD9-520F-42B7-B50E-D2CB7E2B8139Q50640412-C0D40616-CFD0-4164-85B2-75B378D613E5
P2860
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Brief Pain Inventory and i ...... trial endpoint considerations.
@en
The Brief Pain Inventory and i ...... trial endpoint considerations.
@nl
type
label
The Brief Pain Inventory and i ...... trial endpoint considerations.
@en
The Brief Pain Inventory and i ...... trial endpoint considerations.
@nl
prefLabel
The Brief Pain Inventory and i ...... trial endpoint considerations.
@en
The Brief Pain Inventory and i ...... trial endpoint considerations.
@nl
P2093
P2860
P1433
P1476
The Brief Pain Inventory and i ...... trial endpoint considerations.
@en
P2093
Charles Cleeland
Howard I Scher
Steven Passik
Thomas M Atkinson
Tito R Mendoza
P2860
P304
P356
10.1111/J.1526-4637.2009.00774.X
P50
P577
2010-01-15T00:00:00Z